Month: July 2022

Company previously announced positive top-line results from both ReOpen1 and ReOpen2, the landmark trials evaluating XHANCE as a treatment for chronic sinusitis Multiple secondary endpoints from ReOpen2 indicate patients treated with XHANCE experienced improvement in symptoms and quality of life when compared to patients treated with placebo In pooled data from ReOpen1 and ReOpen2, XHANCE demonstrated a benefit relative to placebo on CT scans in patients with chronic sinusitis without nasal polyps YARDLEY, Pa., July 08, 2022 (GLOBE NEWSWIRE) — Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced additional results from the ReOpen trial program evaluating XHANCE for treatment of patients with chronic sinusitis. XHANCE® (fluticasone propionate)...

INDIANA, Pa., July 08, 2022 (GLOBE NEWSWIRE) — First Commonwealth Financial Corporation (NYSE: FCF) announced today that it will host a conference call on Wednesday, July 27, 2022 at 2:00 p.m. Eastern Time to discuss financial results for the quarter ended June 30, 2022. The call will be hosted by T. Michael Price, President and Chief Executive Officer. He will be joined by James R. Reske, Executive Vice President and Chief Financial Officer, Jane Grebenc, Executive Vice President and Chief Revenue Officer and Brian G. Karrip, Executive Vice President and Chief Credit Officer. First Commonwealth will issue a press release reporting its Second Quarter 2022 financial results after the market closes on Tuesday, July 26, 2022. Conference Call InformationWhat: First Commonwealth Financial Corporation     Second Quarter 2022...

AUSTIN, Texas, July 08, 2022 (GLOBE NEWSWIRE) — Atlas Technical Consultants, Inc. (Nasdaq: ATCX) (“Atlas” or the “Company”), a leading Infrastructure and Environmental services provider, announced that L. Joe Boyer, Chief Executive Officer, and Jonathan Parnell, Chief Strategy Officer will participate in the CJS Securities 22nd Annual New Ideas Summer Conference on Tuesday, July 12, 2022. About Atlas Technical ConsultantsHeadquartered in Austin, Texas, Atlas is a leading provider of Infrastructure and Environmental Solutions. We partner with our clients to improve performance and extend the lifecycle of built and natural infrastructure assets stressed by climate, health, and economic impacts. With 3,500+ employees nationwide, Atlas brings deep technical expertise to public- and private-sector clients, integrating services across...

Preliminary Total Revenue for Q2 2022 was approximately $1.0 million Cash as of June 30, 2022 was approximately $16.6 million First commercial customer contract for Acuitas AMR Gene Panel signed in June 2022ROCKVILLE, Md., July 08, 2022 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced today that total preliminary unaudited revenue for the second quarter of 2022 was approximately $1.0 million, up from $0.8 million in the second quarter of 2021. Cash as of June 30, 2022 was approximately $16.6 million. The company announced accomplishment of the following key milestones and recent developments in the second quarter:OpGen signed its first commercial customer contract for the Acuitas...

RALEIGH, N.C., July 08, 2022 (GLOBE NEWSWIRE) — Enact Holdings, Inc. (Nasdaq: ACT) (Enact) today announced it will issue its second quarter earnings release after the market closes on August 1, 2022. Enact will host a conference call to review second quarter 2022 financial results on August 2, 2022 at 8:00 a.m. (ET). Enact’s earnings release, summary presentation and financial supplement will be available through the company’s website, https://ir.enactmi.com/, at the time of their release to the public. Enact’s conference call can be accessed via telephone and Internet. The dial-in number for Enact’s August 2nd conference call is 866-634-2594 or 412-902-4104 (outside the U.S.); participants should ask to be joined into the Enact Holdings, Inc. call. To participate in the call by webcast, register at https://ir.enactmi.com/news-and-events/events...

Treatment Approved for Smallpox, Monkeypox, Cowpox, and Vaccinia Complications NEW YORK, July 08, 2022 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the United Kingdom has approved SIGA’s oral tecovirimat (known in the U.S. as oral TPOXX) for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox in adults and children with a body weight of at least 13kg. “We are very pleased that the UK has taken this important step in health emergency preparedness, not just for the immediate need in the current monkeypox outbreak, but for broader readiness by approving tecovirimat for treatment for a wide range of uses,” said Dr. Phil Gomez, CEO of SIGA. “As we have...

WATERTOWN, Mass., July 08, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Leigh Morgan to its Board of Directors. Ms. Morgan joins Kymera’s Board as a senior executive accomplished in scaling global, profitable, high-performing organizations. “Leigh has distinguished herself as an expert in developing world-class organizations in a wide variety of settings, and I’m thrilled to welcome her to Kymera’s Board of Directors,” said Nello Mainolfi, PhD, Co-Founder, President and Chief Executive Officer of Kymera Therapeutics. “Given our aspirations to evolve Kymera into a fully-integrated, global biopharmaceutical company, her extensive background...

Both ISS and Glass Lewis recommend that Healthcare Realty shareholders vote “FOR” the transaction with HTA at upcoming July 15 special meeting NASHVILLE, Tenn., July 08, 2022 (GLOBE NEWSWIRE) — Healthcare Realty Trust Incorporated (NYSE: HR) (“Healthcare Realty” or the “Company”) today provided an update regarding its strategic combination with Healthcare Trust of America, Inc. (NYSE: HTA) (“HTA”). As previously announced, the transaction consideration includes a stock exchange ratio of 1:1 and a special cash dividend of $4.82 per share to HTA shareholders which totals $1.1 billion. The Company expects to fund the $1.1 billion special cash dividend to HTA shareholders through a combination of asset sales and joint venture transactions at a blended cap rate of 4.8%. Proceeds are expected to be derived from properties under contract...

VANCOUVER, British Columbia, July 08, 2022 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) is pleased to report second quarter 2022 production of 1,359,207 silver ounces (oz) and 9,289 gold oz, for silver equivalent1 (“AgEq”) production of 2.1 million oz. Production continues to outpace the 2022 production guidance of 6.7-7.6 million silver equivalent ounces, totaling 4.1 million AgEq oz for the six months ended June 30, 2022. “Amid ongoing turmoil in the markets due to supply constraints, continued inflation concerns, and uncertainty from the raising of interest rates from historical lows, we had another solid quarter of production” stated Dan Dickson, Chief Executive Officer. “Despite the current macro trends, the Company and precious metals outlook remains optimistic. Given our...

EDMONTON, Alberta, July 08, 2022 (GLOBE NEWSWIRE) — Mineworx Technologies Ltd., (the “Company” or “Mineworx“) (TSXV: MWX) (OTCQB: MWXRF) (FSE: YRS WKN: A2DSW3) announced that it will be offering rights (the “Rights Offering“) to holders of its common shares (“Common Shares“) of record at the close of business on July 18, 2022 (the “Record Date”). Pursuant to the Rights Offering, each holder of Common Shares (a “Shareholder”) will receive one (1) transferable right (each, a “Right”) for each Common Share held as of the Record Date. One (1) Right will entitle the holder thereof to subscribe for one Common Share upon payment of the subscription price of $0.015 per Common Share until 5:00 p.m. (Toronto time) (the “Expiry Time”) on September 12, 2022. Assuming the exercise of all Rights, the Rights Offering will...